MOLECULAR PARTNERS ADS/1 Cash Flow Conversion Efficiency
MOLECULAR PARTNERS ADS/1 cash flow conversion efficiency. Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has a cash flow conversion efficiency ratio of -0.184x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-10.79 Million ≈ $-12.62 Million USD) by net assets (€58.54 Million ≈ $68.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MOLECULAR PARTNERS ADS/1 (2021–2025)
Cash flow conversion efficiency of MOLECULAR PARTNERS ADS/1 from 2021 to 2025. This chart illustrates how MOLECULAR PARTNERS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MOLECULAR PARTNERS ADS/1 stock price for real-time trading data and today's change.
MOLECULAR PARTNERS ADS/1 Cash Flow Conversion Ratio Explained
MOLECULAR PARTNERS ADS/1 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MOLECULAR PARTNERS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their cash flow conversion efficiency. Also see MOLECULAR PARTNERS ADS/1 market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stalexport Autostrady SA
WAR:STX
|
-0.104x |
|
Impiana Hotels Bhd
KLSE:7243
|
-0.111x |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
-0.084x |
|
Fks Multi Agro Tbk
JK:FISH
|
-0.011x |
|
American Well Corp
NYSE:AMWL
|
-0.004x |
|
Gozde Girisim Sermayesi Yatirim Ortakligi AS
IS:GOZDE
|
0.120x |
|
Paragon Globe Bhd
KLSE:3611
|
-0.008x |
|
C&C International Corp.
KQ:352480
|
0.045x |
Annual Cash Flow Conversion Efficiency for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of MOLECULAR PARTNERS ADS/1 from 2021 to 2025. Review 6ML0 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €80.33 Million ≈ $93.92 Million |
€-51.26 Million ≈ $-59.92 Million |
-0.638x | -52.53% |
| 2024-12-31 | €141.64 Million ≈ $165.59 Million |
€-59.25 Million ≈ $-69.27 Million |
-0.418x | -25.08% |
| 2023-12-31 | €176.43 Million ≈ $206.26 Million |
€-59.01 Million ≈ $-68.98 Million |
-0.334x | -166.33% |
| 2022-12-31 | €235.17 Million ≈ $274.93 Million |
€118.57 Million ≈ $138.62 Million |
0.504x | +159.47% |
| 2021-12-31 | €107.29 Million ≈ $125.43 Million |
€-90.95 Million ≈ $-106.33 Million |
-0.848x | -- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more